Ensol Biosciences Inc (140610)

Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis. It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for the treatment of triple negative breast cancer; Moriah 1000 that is in pre-clinical stage for the treatment of Alzheimer’s disease; Shiloah 1000, which is in pre-clinical stage for the treatment of type 1 diabetes; Allose 1000 that is in pre-clinical stage for the treatment of atopic dermatitis; EAD200, a drug for animal anti-cancer drug; and EAD300 for the treatment of porcine reproductive and respiratory syndrome. In addition, the company offers contract drug development; chemistry, manufacturing, and controls contract drug development; and material synthesis and analysis services. Further, it provides KISDD, a knowledge-based in silico drug discovery platform for the screening of new drug candidates for the treatment of a disease; and ETONS, an Ensol Trans-Omics network system. The company was formerly known as Ensoltek Co., Ltd. and changed its name to Ensol Biosciences Inc. in August 2015. Ensol Biosciences Inc. was founded in 2001 and is headquartered in Daejeon, South Korea.